11 Best GLP-1 and Weight Loss Stocks to Invest in

5. Amgen Inc. (NASDAQ:AMGN) 

Number of Hedge Fund Holders: 69

Amgen Inc. (NASDAQ:AMGN) reported that the Phase 3 FORTITUDE-101 trial achieved its primary endpoint. It proved a clinically meaningful and statistically significant improvement in overall survival for patients with FGFR2b-overexpressing, metastatic, or unresectable gastric/gastroesophageal junction cancer treated with bemarituzumab plus chemotherapy (mFOLFOX6). The treatment outperformed chemotherapy alone for non-HER2-positive individuals in this first-line scenario. The threshold for FGFR2b overexpression was ≥10% IHC staining of tumor cells.

Gastric cancer is the world’s fifth greatest cause of cancer death, accounting for approximately 650,000 fatalities per year. The majority of diagnoses come at an advanced stage, which limits the effectiveness of treatment. Jay Bradner, M.D. of Amgen Inc. (NASDAQ:AMGN), pointed out the significance of this advancement in focused therapy. Ocular toxicity, such as punctate keratitis and dry eye, was seen in the bemarituzumab group, which was comparable with previous research but more common. The trial was created in collaboration with Zai Lab, which has regional rights in China and adjacent areas. Results of an additional Phase 3 trial including nivolumab are anticipated in H2 2025. It is ranked fifth on our list of the Best Weight Loss Stocks.